Evidence map›Paper›PMID 36465068›Full record

ArticleRheumatology and immunology research2021

Long-term Outcomes of Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study from CSTAR Registry.

Ziqian Wang, Mengtao Li, Zhizhong Ye, Caifeng Li, Zhijun Li, Xiangpei Li, Lijun Wu, Shengyun Liu, Xiaoxia Zuo, Ping Zhu and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Rheumatology and immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 1 country.

Ziqian WangDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Mengtao LiDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Zhizhong YeDepartment of Rheumatology, The Fourth People's Hospital of Shenzhen Affiliated to Guangdong Medical College, Shenzhen, China.
Caifeng LiDepartment of Rheumatology, Beijing Children Hospital Affiliated to Capital Medical University, Beijing, China.
Zhijun LiDepartment of Rheumatology, The Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Xiangpei LiDepartment of Rheumatology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China.
Lijun WuDepartment of Rheumatology, The People's Hospital of Xinjiang Autonomous Region, Urumqi, China.
Shengyun LiuDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaoxia ZuoDepartment of Rheumatology, Xiangya Hospital, Central South University, Changsha, China.
Ping ZhuDepartment of Clinical Immunology, PLA Specialized Research Institute of Rheumatology and Immunology, Xijing Hospital, Airforce Military Medical University, Xi'an, China.
Zhengang WangDepartment of Rheumatology, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China.
Li MaDepartment of Rheumatology, China-Japan Friendship Hospital Affiliated to the National Health Commission of PRC, Beijing, China.
Miaojia ZhangDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhiduo HouDepartment of Rheumatology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Liqi BiDepartment of Rheumatology, Sino-Japanese friendship Hospital of Jilin University, Changchun, China.
Yanhong WangDepartment of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiuliang ZhaoDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Qian WangDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Xinping TianDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Xiaofeng ZengDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNPeking Union Medical College Hospital · CNAnhui Provincial Hospital · CNBeijing Children’s Hospital · CNBeijing Tongren Hospital · CNBengbu Medical College · CNCapital Medical University · CNCentral South University · CNChina-Japan Friendship Hospital · CNFirst Affiliated Hospital of Zhengzhou University · CNGuangdong Medical College · CNJilin University · CNNanjing Medical University · CNPeople's Hospital of Xinjiang Uygur Autonomous Region · CNShantou University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To study the long-term outcomes, in the context of both mortality and organ damage in patients with systemic lupus erythematosus (SLE) in the Chinese SLE Treatment and Research group (CSTAR) registry cohort. Methods: Patients were enrolled from April 2009 to February 2010 and they were followed up. The demographic data, clinical manifestations, labs test results and imaging examinations, disease activity (SLEDAI-2K), damage scores (SLLIC/Damage Index [SDI]), and medications were collected. Data were censored at either the last clinic visit or telephonic interview. Survival rate was analyzed by Kaplan-Meier (KM) method. COX proportional hazard model was adopted to perform the analysis of predicting factors for mortality and organ damage. Logistic regression analysis was employed to discuss the relationship among mortality, organ damage, and flare. Results: A total of 2104 patients were recruited at baseline and 1494 patients were followed up. The cumulative 1-year, 3-year, and 5-year survival rates were 98.3%, 96.9%, and 95.7%, respectively. Seventy-eight patients died during follow-up, and the main causes of death were infection (34.6%), active disease (26.9%), cardiovascular and cerebrovascular events (5.13%), and malignancy (5.13%). At entry, 247 patients presented with irreversible organ damage and it increased to 398 patients at the endpoint. The major accumulated organ damages were kidney (25.9%), musculoskeletal disease (20.2%), neuropsychiatric disease (12.2%), and pulmonary damage (10.9%). Cox regression analysis further showed that male, late disease onset, delayed diagnosis (diagnosis from disease onset >1 year), baseline organ damage, and specific organ involvements predicted for higher mortality. In addition, early disease onset was a protecting factor for organ damage, and anti-SSA was an independent predicting factor for new organ damage. Logistic regression analysis showed that flare predicted for more organ damage. Conclusion: The 5-year survival rate of Chinese SLE patients has improved and is comparable to Caucasians SLE patients. Disease flare impact on prognosis is the increasing risk of damage development. Early diagnosis, prevention for flare and damage to maintain remission, may improve outcome.

Indexed as

organ damageprognosissystemic lupus erythematosus Flare

Identifiers

PMID36465068
PMCPMC9524789
OpenAlexW4200448794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.